Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Agios Pharma (0HB0) Price & Analysis

0HB0 Stock Chart & Stats

$30.43-$6.48(-17.55%)
At close: 4:00 PM EDT
$30$32.5$35$37.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$29.97 - $37.23
52-Week Range
$22.40 - $45.81
Previous Close
$36.91
Volume
429
Average Volume (3M)
372
Market Cap
$1.82B
Enterprise Value
$1.62B
Total Cash (Recent Filing)
$617.58M
Total Debt (Recent Filing)
$31.17M
Price to Earnings (P/E)
―
Beta
1.51
Next Earnings
Nov 05, 2026
EPS Estimate
-1.24
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Strong revenue growth and Q2 launch performance indicate that Agios is converting its approved-product opportunity into commercial sales. Continued adoption can broaden the revenue base, improve operating leverage over time, and support investment in additional hematology indications.

Strong Liquidity And Low Leverage

Agios has substantial liquidity relative to its low debt burden, providing financial flexibility to fund clinical development, commercial expansion, and regulatory activities. This balance-sheet capacity reduces near-term financing pressure while the company works toward improving profitability.

Pipeline Advancement

Multiple programs are advancing across hematology and metabolic disease, giving Agios opportunities to diversify beyond its current commercial product. Progress into later-stage development can expand the addressable portfolio and create additional future revenue opportunities.

Bears Say

Deep Losses And Cash Burn

Persistent losses and substantial negative cash flow show that current operations do not yet fund the company’s development and commercial activities. Continued spending at this level can consume liquidity and increase the importance of future product growth or external financing.

High Operating Expenses

Rising research and selling expenses are necessary to advance programs and support commercialization, but they currently widen the gap between revenue and operating costs. Unless investment produces sustained sales growth or pipeline value, operating leverage and earnings improvement may remain limited.

Delayed Sickle-cell Regulatory Catalyst

The extended review timeline postpones potential regulatory validation and the opportunity to commercialize mitapivat in sickle cell disease. This delays a possible expansion of the addressable market and prolongs dependence on existing products and pipeline execution.

Agios Pharma News

0HB0 FAQ

What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest share price was $22.40 and its highest was $45.81 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.82B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.655 by -$0.035.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma pays a Notavailable dividend of $0.285 which represents an annual dividend yield of ―. See more information on Agios Pharma dividends here
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.24.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.655. Following the earnings report the stock price went down -5.966%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in GB:0HB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology